Case Study
Actionable results to inform your treatment decisions
Use the PrismRA test to identify a patient’s likelihood of inadequate response to TNFi therapy, whenever the result can inform therapeutic selection and treatment decision-making. The PrismRA test may be ordered for patients who are naïve or exposed to targeted therapies.
Even patients with similar clinical presentations can vary widely in their likelihood of response to TNFi therapy. This below case study offers an example of two similar patients with rheumatoid arthritis (RA) whose providers administered the PrismRA test to help guide their treatment decisions.
Case Study
Two similar female patients are starting targeted therapy.
Case Study
Two similar female patients are starting targeted therapy.
Mary
Age:
57
Time Since Dx:
1 year
Sarah
Age:
57
Time Since Dx:
4 years
On Methotraxate
On Methotraxate
Yes
On Methotraxate
Yes
Anti-CCP
Anti-CCP
Negative
Anti-CCP
Negative
Rheumatoid factor
Rheumatoid factor
Negative
Rheumatoid factor
Positive
C-reactive protein
C-reactive protein
0.78 mg/L
C-reactive protein
3.63 mg/L
Swollen joint count
Swollen joint count
8
Swollen joint count
8
Tender joint count
Tender joint count
15
Tender joint count
12
Physician global
Physician global
50
Physician global
43 Patient's PrismRA results and proposed treatment decisions
PrismRA Score
PrismRA Score
12.2
PrismRA Score
5.4 Likelihood of non-response
Likelihood of non-response
High
Likelihood of non-response
Not Detected Actual response to TNFi Therapy
Actual response to TNFi Therapy
Inadequate
Actual response to TNFi Therapy
Adequate Proposed treatment decision
Proposed treatment decision
Alternative Therapy
Proposed treatment decision
TNFi Reflects actual patients from validation study
